Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for Gregory Guido�
12.88
+0.57 (4.63%)
Real-time:   11:34AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.25 - 12.89
52 week 10.29 - 18.85
Open 12.53
Vol / Avg. 257,127.00/590,129.00
Mkt cap 836.31M
P/E     -
Div/yield     -
EPS -0.33
Shares 66.99M
Beta 0.97
Inst. own 98%
Nov 20, 2014
Endologix Inc Investor Meeting
Nov 20, 2014
Endologix Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 18, 2014
Endologix Inc at Stifel Healthcare Conference
Nov 11, 2014
Endologix Inc at Stephens Fall Investment Conference
Oct 30, 2014
Q3 2014 Endologix Inc Earnings Call - Webcast
Oct 30, 2014
Q3 2014 Endologix Inc Earnings Release
Sep 29, 2014
Preliminary Q3 2014 Endologix Inc Earnings Release
Sep 29, 2014
Preliminary Q3 2014 Endologix Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -37.52% -12.15%
Operating margin -23.49% -14.27%
EBITD margin - -6.02%
Return on average assets -21.51% -7.63%
Return on average equity -40.13% -16.14%
Employees 482 -
CDP Score - -

Address

2 Musick
IRVINE, CA 92618-1631
United States - Map
+1-949-5957200 (Phone)
+1-949-4579561 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company�s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company�s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.

Officers and directors

John McDermott Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 52
Bio & Compensation  - Reuters
Shelley B. Thunen Chief Financial Officer and Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Todd G. Abraham Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Joseph A. DeJohn Vice President - Sales
Age: 53
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 48
Bio & Compensation  - Reuters
Charles Love Vice President - Clinical Affairs
Age: 52
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters
Janet Fauls Director - Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters